摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N,2-diphenylquinoline-4-carboxamide | 110662-85-6

中文名称
——
中文别名
——
英文名称
N,2-diphenylquinoline-4-carboxamide
英文别名
2-phenyl-quinoline-4-carboxylic acid anilide;2-Phenyl-chinolin-4-carbonsaeure-anilid
N,2-diphenylquinoline-4-carboxamide化学式
CAS
110662-85-6
化学式
C22H16N2O
mdl
MFCD00249830
分子量
324.382
InChiKey
LLMJQNQPWAGSDT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N,2-diphenylquinoline-4-carboxamide苯胺 在 xylene 、 三氯氧磷 作用下, 生成 2,N-diphenyl-quinoline-4-carbonimidic acid anilide
    参考文献:
    名称:
    Delaby et al., Bulletin de la Societe Chimique de France, 1956, p. 1294,1295
    摘要:
    DOI:
  • 作为产物:
    描述:
    2-苯基-4-喹啉羧酸氯化亚砜三乙胺 作用下, 以 二氯甲烷 为溶剂, 反应 4.0h, 生成 N,2-diphenylquinoline-4-carboxamide
    参考文献:
    名称:
    Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates
    摘要:
    药物及药物候选物代谢物的鉴定和定量通常使用液相色谱-质谱联用技术 (LC-MS) 进行。最佳实践是生成以代谢物与内标的标准曲线。然而,为了避免代谢物合成的困难,有时会使用底物来准备标准曲线,假设底物和代谢物的信号是等效的。我们使用一系列非常相似的化合物,这些化合物经历共同的代谢反应,测试了这一假设所带来的误差,采用了传统流动电喷雾电离 LC-MS 和低流量捕获喷雾电离 (CSI) LC-MS 方法。文中展示了四种不同转化类型(O-去甲基化、N-去甲基化、芳香族羟基化和苄基羟基化)的标准曲线差异。结果表明,在20种底物-代谢物组合中的18种情况下,两种方法中底物和代谢物的信号在统计上是显著不同的。标准曲线的斜率比率最高可变化4倍,但CSI方法的变化略小。
    DOI:
    10.1124/dmd.111.040865
点击查看最新优质反应信息

文献信息

  • SUBSTITUTED N,2-DIARYLQUINOLINE-4-CARBOXAMIDES AND THE USE THEREOF AS ANTI-INFLAMMATORY AGENTS
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20170260140A1
    公开(公告)日:2017-09-14
    The present application relates to novel substituted N,2-diarylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and/or inflammatory disorders.
    本申请涉及新颖的取代N,2-二芳基喹啉-4-甲酰胺衍生物,其制备方法,单独或组合使用以治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是用于治疗和/或预防纤维化和/或炎症性疾病。
  • Design, synthesis and biological evaluation of 2-phenylquinoline-4-carboxamide derivatives as a new class of tubulin polymerization inhibitors
    作者:Li Zhu、Kaixiu Luo、Ke Li、Yi Jin、Jun Lin
    DOI:10.1016/j.bmc.2017.09.004
    日期:2017.11
    inhibitory effect on tubulin polymerization. In addition, immunofluorescence and flow cytometry analysis revealed that selected compounds caused disruption of the mitotic spindle assembly and G2/M phase arrest of the cell cycle, which correlated with proliferation inhibitory activity. Molecular docking analysis demonstrated the interaction of 7b at the colchicine binding site of tubulin. These results indicate
    合成,表征和评估了一系列新的2-苯基喹啉-4-羧酰胺衍生物对五种癌细胞系(Hela,SK-OV-3,HCT116,A549和MDA-MB-468)和正常人的抗增殖活性胎儿肺成纤维细胞系,MRC-5。其中,化合物7b在体外显示出对SK-OV-3和HCT116细胞系的有效细胞毒活性,IC 50值分别为0.5和0.2μM。通常,抗增殖活性与秋水仙碱结合位点的结合特性和对微管蛋白聚合的抑制作用有关。此外,免疫荧光和流式细胞仪分析表明,选定的化合物导致有丝分裂纺锤体装配和G 2的破坏细胞周期的/ M期停滞,与增殖抑制活性有关。分子对接分析表明7b在微管蛋白的秋水仙碱结合位点相互作用。这些结果表明这些化合物是用于有效治疗癌症的微管蛋白聚合的有希望的抑制剂。
  • SUBSTITUTED N-ARYLETHYL-2-AMINOQUINOLINE-4-CARBOXAMIDES AND USE THEREOF
    申请人:Bayer Aktiengesellschaft
    公开号:US20200157073A1
    公开(公告)日:2020-05-21
    The present application relates to novel substituted N-arylethyl-2-aminoquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    本申请涉及新型取代N-芳基乙基-2-氨基喹啉-4-羧酰胺衍生物,其制备方法,其单独或与其他物质结合用于治疗和/或预防疾病,以及用于制备治疗和/或预防疾病的药物,特别是用于治疗和/或预防纤维化和炎症性疾病。
  • SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF
    申请人:Bayer Aktiengesellschaft
    公开号:US20200031775A1
    公开(公告)日:2020-01-30
    The present application relates to novel substituted N-arylethyl-2-arylquinoline-4-carboxamide derivatives, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of fibrotic and inflammatory disorders.
    本申请涉及新型取代N-芳基乙基-2-芳基喹啉-4-羧酰胺衍生物,其制备方法,其单独或组合用于治疗和/或预防疾病的用途,以及其用于生产治疗和/或预防疾病的药物的用途,特别是用于治疗和/或预防纤维化和炎症性疾病。
  • Synthesis, Characterization, Biological Screening, ADME and Molecular Docking Studies of 2-Phenyl Quinoline-4-Carboxamide Derivatives
    作者:P. Raghurama Shetty、G. Shivaraja、G. Krishnaswamy、K. Pruthviraj、Vivek Chandra Mohan、S. Sreenivasa
    DOI:10.14233/ajchem.2020.22583
    日期:——

    In this work, some 2-phenyl quinoline-4-carboxamide derivatives (5a-j) were synthesized via base catalyzed Pfitzinger reaction of isatin and acetophenone followed by C-N coupling reaction using POCl3 and assessed them for their in vitro antimicrobial and anticancer activity. The structure of newly synthesized compound were established by FT-IR, 1H & 13C NMR and Mass spectrometric analysis. The synthesized carboxamides were subjected to preliminary in vitro antibacterial activity as well as for antifungal activity. Results of antibacterial activity were compared with standard antibacterial (ciprofloxocin) and antifungal (fluconozole). Among the tested compounds, 5d, 5f and 5h exhibited promising activity with zone of inhibition ranging from 10 to 25 mm. Further, the anticancer activity determined using MTT assay against two cancer cell lines. Compounds 5b, 5d, 5f and 5h showed good anticancer activity among all the other derivatives. In order to correlate the in vitro results, in silico ADME and Molecular docking studies were carried out for (5a-j). ADME properties results showed that all the compounds obey rule of Five rule except 5a, 5e and 5g compound. Molecular docking studies of the synthesized compounds showed good binding affinity through hydrogen bond interactions with key residues on active sites as well as neighboring residues within the active site of chosen target proteins viz. antibacterial, antifungal and anticancer. Comparison of both results of in silico as well as in vitro investigation suggests that the synthesized compounds may act as potential antimicrobial as well as anticancer agents.

    在这项工作中,通过以异喹啉和苯乙酮为原料进行碱催化的菲兹杰反应合成了一些2-苯基喹啉-4-羧酰胺衍生物(5a-j),随后通过POCl3进行C-N偶联反应,并评估它们的体外抗微生物和抗癌活性。新合成化合物的结构通过FT-IR、1H和13C NMR以及质谱分析得以确定。合成的羧酰胺类化合物进行了初步的体外抗菌活性和抗真菌活性测试。抗菌活性的结果与标准抗菌药物(环丙沙星)和抗真菌药物(氟康唑)进行了比较。在测试的化合物中,5d、5f和5h表现出良好的活性,抑制区直径范围为10至25毫米。此外,使用MTT法对两种癌细胞系进行了抗癌活性评定。其中,化合物5b、5d、5f和5h在所有衍生物中显示出良好的抗癌活性。为了将体外结果相关联,对(5a-j)进行了ADME和分子对接研究。ADME性质结果显示,除了5a、5e和5g化合物外,所有化合物都符合五原则。合成化合物的分子对接研究显示出良好的结合亲和力,通过与活性位点上的关键残基以及活性位点内的相邻残基进行氢键相互作用。体外和体内研究结果的比较表明,合成的化合物可能作为潜在的抗微生物和抗癌剂。
查看更多